Centrally acting drugs for erectile dysfunction: Do they have a future? |
| |
Authors: | Petter Hedlund MD PhD |
| |
Institution: | (1) Department of Clinical Pharmacology, Lund University Hospital, S-221 85 Lund, Sweden |
| |
Abstract: | Initial placebo-controlled trials with sublingual apomorphine showed promising results for the drug as an option in the pharmacologic
management of erectile dysfunction (ED). More recent studies propose poor erectile effects by apomorphine sublingual in patients
with diabetes and fewer benefits than sildenafil in patients with ED. In June this year, the European Medicines Agency declared
that due to commercial reasons, the marketing authorization for Uprima (Abbott Laboratories, Abbott Park, IL) was not renewed,
and the drug is no longer available in the European Union. This does not mean that receptor functions in the central nervous
system are uninteresting pharmacologic targets for ED. Experiences with apomorphine sublingual in humans should be acknowledged
for a more careful preclinical and clinical characterization of agents with a central nervous system site of action. This
article focuses on information obtained from human trials of central acting drugs for ED. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|